NASDAQ: $BNTX A Breakthrough in Lung Cancer Research In a significant development for oncology, BioNTech and Bristol Myers Squibb have released encouraging global Phase 2 clinical trial data for their investigational bispecific antibody, pumitamig. The study focused on patients with advanced non-small cell lung cancer (NSCLC) who have progressed following standard-of-care therapies. Understanding the Clinical…